Emerging biopharmas have gradually taken over the R&D pipeline, producing two-thirds of all new drugs in 2022, a finding one financial biotech player called “stunning.”
“Emerging biopharma has been rising at roughly 4% a year for each of the last five years,” Tim Opler, Ph.D., managing director for life sciences investment bank Torreya, said during a March 29 presentation of IQVIA’s report on global R&D trends. Opler, citing the IQVIA data, dubbed the stat an “absolutely stunning finding.”
“Go back to, say, the year 2005,” Opler said. “If someone told you that two-thirds of our industry would be driven on the R&D side by emerging biopharma—it would be unthinkable. If one were to project that trend forward, what it would suggest is that we could have a day when we do this talk, say in 2027 or 2028, where 80% of the industry’s pipeline is coming from emerging companies.”
So-called emerging biopharmas (EBPs)—a term for companies with less than $200 million in R&D spending and annual sales lower than $500 million—were responsible for 67% of 2022’s R&D pipeline, according to IQVIA’s report. This is a jump from about 63% pipeline ownership the year prior, 51% five years ago and 33% back in 2002 ago, according to the report.
However, the rise of EBPs underscores the slowly receding presence of Big Pharma in R&D.
“If two-thirds of the pipeline is from emerging biopharma, what’s going on with Big Pharma?” Opler asked during the presentation. “I do worry a bit about Big Pharma R&D productivity and I think that’s a topic to be addressed in the five years ahead.”
Big Pharmas represented just 23% of pipeline activity in 2022, a steep drop from 48% back in 2002. The decline has somewhat softened in the last five years, according to IQVIA’s chart, though the number of EBPs has shot up 26% in the same period.
The number of R&D deals between pharmas also dipped 25% from 2021, while an increasing share of deals involved EBPs with larger companies.
This isn’t to say Big Pharma isn’t still greatly involved in biotech. In 2022, the 15 largest pharmas put down a record-setting $138 billion for R&D, a 43% jump from five years prior and a number that represents 18.8% of their recorded sales.
By Gabrielle Masson
Source: fiercebiotech.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
